Syndax Pharmaceuticals

IPO

Home - Syndax

Public · Waltham, United States · Founded 2005 · $152.6M raised

Employees
51–200
Founded
2005
Business Model
B2B
Website
syndax.com
Total Funding
$152.6M
Last Round
$80.0M Series CAug 2015
Rounds
4
Type
Public

Totals include recorded grants and other qualifying funding, not just equity. What counts toward funding.

About

Syndax Pharmaceuticals is a commercial-stage biopharmaceutical company advancing innovative cancer therapies. Its mission is to obtain regulatory approval and commercialize drugs that extend and improve the lives of cancer patients by drawing on the newest scientific research and advances, collaborating with determined problem solvers, and identifying value in overlooked aspects of science. Syndax focuses on menin inhibition for KMT2A-rearranged acute leukemias and NPM1-mutated acute myeloid leukemia, plus an anti-CSF-1R monoclonal antibody program for chronic graft-versus-host disease.

Summary

Syndax Pharmaceuticals is a Biotech company based in Waltham, United States, founded in 2005. It has raised $152.6M in total across 4 rounds, most recently a $80.0M Series C round in Aug 2015. Investors include Royalty Pharma, Delos Capital and Fidelity Management.

Tech & App Stack

4 technologies & apps tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding & Exit History

Debt FinancingDebt FinancingNov 2024
$350.0M

Sign up to see all 6 events

Funding: Series A through Series C. Amounts, valuations, and investors where available.

Investors

Similar Companies

Pharmaceutical Product Development, Inc. (PPD)Acquired

Global contract research organization providing comprehensive drug development and laboratory ser...

Wilmington, United States10001+Biotech, Healthcare
Private EquityTotal funding$3.9BJan 2019
Warner ChilcottAcquired

Specialty pharmaceutical company

Rockaway, United States1001–5000Biotech, Healthcare
Private EquityTotal funding$3.0BJan 2004
Altos Labs

Altos Labs combines academic science and industry development to create medicines that restore ce...

San Francisco, United States501–1000Life Sciences, Biotech
Series ATotal funding$3.0BJan 2022
Syneos HealthAcquired

Integrated biopharmaceutical solutions company

Burlington, United States10001+Biotech, Healthcare
Private EquityTotal funding$3.0BMay 2017
BeiGeneIPO

BeOne Medicines develops transformative oncology medicines through rigorous science, an accelerat...

Cambridge, United States10001+Biotech, Oncology
Corporate RoundTotal funding$2.8BJan 2020
BridgeBioIPO

BridgeBio develops treatments for genetic conditions through autonomous condition-focused teams s...

San Francisco Bay Area, United States201–500Biotech, Healthcare
Growth EquityTotal funding$2.7BJul 2026

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

Syndax Pharmaceuticals on Indexed.vc
<a href="https://indexed.vc/companies/syndax-pharmaceuticals"><img src="https://indexed.vc/api/badge/company/syndax-pharmaceuticals" alt="Syndax Pharmaceuticals on Indexed.vc" width="260" height="76" /></a>